Morning Briefing
Summaries of health policy coverage from major news organizations
EpiPen-Maker Won't Testify At Senate Hearing
Stat: Mylan Refuses To Testify At Senate Hearing About EpiPen Costs To Medicaid
In a move that angered a key Senate lawmaker, Mylan Pharmaceuticals has declined to testify at a planned Nov. 30 Senate hearing to review a $465 million settlement the drug maker purportedly reached with the US Department of Justice for shortchanging Medicaid. In a letter to Sen. Chuck Grassley (R-Iowa), who chairs the Senate Judiciary Committee, an attorney for Mylan explained the company will not appear for three reasons – the “stated focus of the hearing,” because the hearing involves a “pending matter,” because both the Justice Department and the Centers for Medicare & Medicaid Services have already said they will not send officials to testify. (Silverman, 11/21)
The Associated Press: EpiPen Manufacturer Will Be A No-Show At Senate Hearing
Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen. In a letter to the Senate Judiciary Committee, an attorney for Mylan said company executives wouldn't testify at the Nov. 30 hearing because the settlement is a pending matter and the Justice Department would also not be attending. (Jalonick, 11/21)
